Return to Leukemia & Lymphoma Specialty Channel

Leukemia & Lymphoma Interactive Features

Long-term follow-up results from the FoRT study shows that the optimal RT dose for patients with indolent NHL is _________.
Fill in the Blank: Long-term follow-up results from the FoRT study show that the optimal radiotherapy dose to treat patients with indolent non-Hodgkin lymphoma is ___ Gy in ___ fractions, according…
True or False: Brentuximab vedotin combined with chemotherapy is significantly more effective than chemotherapy alone in patients with CD30-positive peripheral T-cell lymphomas.
True or False: In the phase 2 ZUMA-2 clinical trial, anti-CD19 CAR-T therapy with KTE-X19 yielded no benefit in the majority of patients with relapsed or refractory MCL.
True or False: Rituximab plus bendamustine administered before autologous SCT in patients with MCL led to very low rates of durable remission in a pooled analysis by Merryman et al.
True or False: Bortezomib maintenance therapy after transplantation yields no positive effect in young patients with MCL.
True or False: MRD-negativity has been shown to significantly improve OS in patients with FL.
True or False: BTKi therapy is an effective therapy option for patients with heavily pretreated, high-risk CLL that has progressed with venetoclax.
Stay in the know.
OncNet Newsletter